Selective inhibition of cell death in malignant vs normal B-cell precursors: Implications for cAMP in development and treatment of BCP-ALL

Blood

Volumn 121, Issue 10, 2013, Pages 1805-1813

  Naderi, Elin Hallan ^a   Ugland, Hege Katrin ^a   Diep, Phoi Phoi ^b   Josefsen, Dag ^b   Ruud, Ellen ^b   Naderi, Soheil ^a   Blomhoff, Heidi Kiil ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; FORSKOLIN; PROSTAGLANDIN E2; PROTEIN P53;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA; BLAST CELL; CANCER PATIENT; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALIGNANT TRANSFORMATION; PARACRINE SIGNALING; PRE B LYMPHOCYTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84876498746     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-452698     Document Type: Article

References (50)

1. Onciu M. Acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23(4):655-674.
2. Gatta G, Zigon G, Capocaccia R, et al EUROCARE Working Group. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer. 2009;45(6): 992-1005.
3. Gaynon PS, Angiolillo AL, Carroll WL, et al Children's Oncology Group. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report. Leukemia. 2010;24(2):285-297.
4. Robison LL. Late effects of acute lymphoblastic leukemia therapy in patients diagnosed at 0-20 years of age. Hematology Am Soc Hematol Educ Program. 2011;2011:238-242.
5. Ness KK, Armenian SH, Kadan-Lottick N, et al. Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health. Expert Rev Hematol. 2011;4(2):185-197.
6. Gǒkbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol. 2009; 46(1):64-75.
7. Junttila MR, Evan GI. p53 -A Jack of all trades but master of none. Nat Rev Cancer. 2009;9(11): 821-829.
8. Fenaux P, Jonveaux P, Quiquandon I, et al. Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia. 1992;6(1):42-46.
9. Gu L, Zhu N, Findley HW, et al. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia. 2008;22(4):730-739. (Pubitemid 351552622)
10. Wiman KG. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 2006;13(6):921-926.
11. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006;127(7):1323-1334. (Pubitemid 44960417)
12. Dickins RA, McJunkin K, Hernando E, et al. Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet. 2007;39(7):914-921. (Pubitemid 47014488)
13. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445(7128): 661-665. (Pubitemid 46232887)
14. Naderi EH, Findley HW, Ruud E, et al. Activation of cAMP signaling inhibits DNA damage-induced apoptosis in BCP-ALL cells through abrogation of p53 accumulation. Blood. 2009;114(3):608-618.
15. Naderi EH, Jochemsen AG, Blomhoff HK, et al. Activation of cAMP signaling interferes with stress-induced p53 accumulation in ALL-derived cells by promoting the interaction between p53 and HDM2. Neoplasia. 2011;13(7):653-663.
16. Torgersen KM, Aandahl EM, Tasken K. Molecular architecture of signal complexes regulating immune cell function. Handb Exp Pharmacol. 2008;(186):327-363.
17. Simkin NJ, Jelinek DF, Lipsky PE. Inhibition of human B cell responsiveness by prostaglandin E2. J Immunol. 1987;138(4):1074-1081. (Pubitemid 17017887)
18. Kammer GM. The adenylate cyclase-cAMPprotein kinase A pathway and regulation of the immune response. Immunol Today. 1988;9(7-8): 222-229.
19. Malissein E, Reynaud S, Bordessoule D, et al. PGE(2) receptor subtype functionality on immature forms of human leukemic blasts. Leuk Res. 2006;30(10):1309-1313. (Pubitemid 44223725)
20. Saarinen-Pihkala UM, Parto K, Riikonen P, et al. RALLE pilot: response-guided therapy for marrow relapse in acute lymphoblastic leukemia in children. J Pediatr Hematol Oncol. 2012;34(4): 263-270.
21. Ugland H, Naderi S, Brech A, et al. cAMP induces autophagy via a novel pathway involving ERK, cyclin E and Beclin 1. Autophagy. 2011;7(10): 1199-1211.
22. Fielding AK. Current therapeutic strategies in adult acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2011;25(6):1255-1279, viii.
23. Sunahara RK, Taussig R. Isoforms of mammalian adenylyl cyclase: multiplicities of signaling. Mol Interv. 2002;2(3):168-184.
24. Seamon KB, Daly JW. Forskolin: its biological and chemical properties. Adv Cyclic Nucleotide Protein Phosphorylation Res. 1986;20:1-150.
25. Uphoff CC, MacLeod RA, Denkmann SA, et al. Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines. Leukemia. 1997;11(3): 441-447. (Pubitemid 27120997)
26. Shanahan MF, Morris DP, Edwards BM. [3H]forskolin. Direct photoaffinity labeling of the erythrocyte D-glucose transporter. J Biol Chem. 1987;262(13):5978-5984. (Pubitemid 17103032)
27. Ono K, Fozzard HA, Hanck DA. A direct effect of forskolin on sodium channel bursting. Pflugers Arch. 1995;429(4):561-569.
28. Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev. 2008; 18(1):27-34. (Pubitemid 351694443)
29. Harris RE. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem. 2007;42:93-126.
30. Kleiveland CR, Kassem M, Lea T. Human mesenchymal stem cell proliferation is regulated by PGE2 through differential activation of cAMPdependent protein kinase isoforms. Exp Cell Res. 2008;314(8):1831-1838.
31. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815-1822. (Pubitemid 40223708)
32. Konopleva M, Andreeff M. Targeting the leukemia microenvironment. Curr Drug Targets. 2007;8(6): 685-701. (Pubitemid 47603399)
33. Blom B, Spits H. Development of human lymphoid cells. Annu Rev Immunol. 2006;24:287-320.
34. Halliwell B. Oxidative stress in cell culture: an under-appreciated problem? FEBS Lett. 2003; 540(1-3):3-6. (Pubitemid 36398024)
35. Secchiero P, di Iasio MG, Gonelli A, et al. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des. 2008;14(21):2100-2110.
36. Cohen LA, Chan PC. Intracellular cAMP levels in normal rat mammary gland and adenocarcinoma. In vivo vs in vitro. Life Sci. 1975;16(1):107-115.
37. Brønstad GO, Gladhaug IP, Haffner F, et al. The regulation of cyclic AMP levels in cultured MH1C1 rat hepatoma cells and in solid tumours derived from MH1C1 cell inoculates. Anticancer Res. 1987;7(2):155-160. (Pubitemid 17117939)
38. Jarnaess E, Task'en K. Spatiotemporal control of cAMP signalling processes by anchored signalling complexes. Biochem Soc Trans. 2007;35(Pt 5): 931-937. (Pubitemid 350206399)
39. Neary CL, Nesterova M, Cho YS, et al. Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion. Oncogene. 2004;23(54):8847-8856. (Pubitemid 39593299)
40. Cho-Chung YS, Clair T. The regulatory subunit of cAMP-dependent protein kinase as a target for chemotherapy of cancer and other cellular dysfunctional-related diseases. Pharmacol Ther. 1993;60(2):265-288. (Pubitemid 24117379)
41. Bossis I, Stratakis CA. Minireview: PRKAR1A: normal and abnormal functions. Endocrinology. 2004;145(12):5452-5458. (Pubitemid 39564583)
42. Cho-Chung YS, Pepe S, Clair T, et al. cAMPdependent protein kinase: role in normal and malignant growth. Crit Rev Oncol Hematol. 1995; 21(1-3):33-61. (Pubitemid 26051647)
43. Cho-Chung YS, Nesterova MV. Tumor reversion: protein kinase A isozyme switching. Ann N Y Acad Sci. 2005;1058:76-86.
44. Dalton WS, Hazlehurst L, Shain K, et al. Targeting the bone marrow microenvironment in hematologic malignancies. Semin Hematol. 2004;41(2 Suppl 4):1-5. (Pubitemid 38649812)
45. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010; 11(11):1096-1106.
46. Schlossmacher G, Stevens A, White A. Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. J Endocrinol. 2011;211(1):17-25.
47. Malcher-Lopes R, Buzzi M. Glucocorticoidregulated crosstalk between arachidonic acid and endocannabinoid biochemical pathways coordinates cognitive-, neuroimmune-, and energy homeostasis-related adaptations to stress. Vitam Horm. 2009;81: 263-313.
48. Nayjib B, Zeddou M, Drion P, et al. In vivo administration of a PKA type I inhibitor (Rp-8-BrcAMPS) restores T-cell responses in retrovirusinfected mice. The Open Immunology Journal. 2008;1:20-24.
49. Brudvik KW, Paulsen JE, Aandahl EM, et al. Protein kinase A antagonist inhibits b-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in Apc(Min/1) mice. Mol Cancer. 2011;10:149.
50. Hunger SP. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia. Hematology Am Soc Hematol Educ Program. 2011;2011: 361-365.